In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synthelabo's device sales up 5%:

This article was originally published in Clinica

Executive Summary

Sales at Synthelabo's pacemaker division, Ela Medical, increased 5% to Fr627 million ($100 million) in 1997. During the year, the French company launched its dual chamber defibrillator, Defender II, in Europe. The product is in clinical trials in the US. Synthelabo's new pacemaker, Talent, is in clinical trials in Europe. The company recently announced a global co-marketing deal with US company Angeion (see Clinica No 778, p 7). Sales of the company's catheter division, Porges, rose 7% to Fr213 million.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts